Wells Fargo & Company MN raised its stake in shares of Alkermes PLC (NASDAQ:ALKS) by 6.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 260,694 shares of the company’s stock after buying an additional 15,599 shares during the period. Wells Fargo & Company MN owned approximately 0.17% of Alkermes PLC worth $12,261,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of the stock. Primecap Management Co. CA acquired a new position in Alkermes PLC during the second quarter valued at approximately $108,286,000. Westfield Capital Management Co. LP raised its position in Alkermes PLC by 317.7% in the second quarter. Westfield Capital Management Co. LP now owns 1,272,500 shares of the company’s stock valued at $54,997,000 after buying an additional 967,862 shares during the period. Bank of New York Mellon Corp raised its position in Alkermes PLC by 81.4% in the second quarter. Bank of New York Mellon Corp now owns 1,234,164 shares of the company’s stock valued at $53,342,000 after buying an additional 553,717 shares during the period. UBS Asset Management Americas Inc. raised its position in Alkermes PLC by 64.4% in the second quarter. UBS Asset Management Americas Inc. now owns 1,186,558 shares of the company’s stock valued at $51,284,000 after buying an additional 464,782 shares during the period. Finally, Vanguard Group Inc. raised its position in Alkermes PLC by 3.2% in the second quarter. Vanguard Group Inc. now owns 11,050,080 shares of the company’s stock valued at $477,585,000 after buying an additional 343,746 shares during the period. 95.97% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Alkermes PLC (NASDAQ:ALKS)

Shares of Alkermes PLC (NASDAQ:ALKS) traded down 0.54% during midday trading on Tuesday, reaching $57.46. 346,110 shares of the company were exchanged. The company’s 50-day moving average price is $52.71 and its 200 day moving average price is $47.68. Alkermes PLC has a 52-week low of $27.14 and a 52-week high of $80.71. The stock’s market capitalization is $8.73 billion.

Alkermes PLC (NASDAQ:ALKS) last released its earnings results on Wednesday, November 2nd. The company reported ($0.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by $0.03. The company earned $180.20 million during the quarter, compared to the consensus estimate of $186.39 million. Alkermes PLC had a negative return on equity of 12.75% and a negative net margin of 36.92%. Alkermes PLC’s revenue for the quarter was up 18.0% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.19) EPS. On average, equities analysts predict that Alkermes PLC will post ($0.20) earnings per share for the current year.

WARNING: “Alkermes PLC (ALKS) Position Increased by Wells Fargo & Company MN” was originally reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this piece of content on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2016/11/29/alkermes-plc-alks-position-increased-by-wells-fargo-company-mn.html.

ALKS has been the topic of several recent analyst reports. Jefferies Group increased their target price on Alkermes PLC from $62.00 to $70.00 and gave the company a “buy” rating in a report on Friday, October 21st. Morgan Stanley raised Alkermes PLC from an “underweight” rating to a “hold” rating and set a $62.00 target price on the stock in a report on Friday, October 21st. Leerink Swann initiated coverage on Alkermes PLC in a report on Tuesday, October 4th. They issued an “outperform” rating and a $57.00 target price on the stock. Citigroup Inc. increased their target price on Alkermes PLC from $44.00 to $53.00 and gave the company a “neutral” rating in a report on Tuesday, September 27th. Finally, Zacks Investment Research lowered Alkermes PLC from a “buy” rating to a “hold” rating in a report on Tuesday, September 27th. One analyst has rated the stock with a sell rating, three have issued a hold rating and seven have assigned a buy rating to the company. Alkermes PLC presently has a consensus rating of “Buy” and a consensus price target of $61.64.

In other Alkermes PLC news, Director Paul J. Mitchell sold 2,000 shares of the company’s stock in a transaction dated Tuesday, September 6th. The shares were sold at an average price of $45.92, for a total value of $91,840.00. Following the completion of the transaction, the director now owns 10,000 shares in the company, valued at approximately $459,200. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Richard F. Pops sold 30,000 shares of the company’s stock in a transaction dated Tuesday, November 22nd. The stock was sold at an average price of $58.66, for a total transaction of $1,759,800.00. Following the completion of the transaction, the director now owns 638,962 shares of the company’s stock, valued at approximately $37,481,510.92. The disclosure for this sale can be found here. 4.75% of the stock is currently owned by insiders.

Alkermes PLC Company Profile

Alkermes Public Limited Company is a biopharmaceutical company. The Company is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of approximately 20 products and a clinical pipeline of product candidates that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis.

5 Day Chart for NASDAQ:ALKS

Receive News & Stock Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related stocks with our FREE daily email newsletter.